What does the evidence show for CBG and sleep?
This was tested, and the evidence does not support it. In a randomised, triple-blind, placebo-controlled trial in veterans — 63 randomised, 35 completing without major protocol deviations — CBG at 25 mg daily for two weeks then 50 mg daily for two weeks did not improve sleep quality more than placebo: the primary endpoint was null, and the disability and PTSD-symptom measures showed the same pattern. Scores improved in both arms, which is exactly what a placebo control exists to separate. CBG was well tolerated. The sponsor is a CBG product company (Metta Medical dba LEVEL), and the authors state that no firm conclusion on efficacy for sleep can be made. This is the only randomised placebo-controlled test of a repeated-dose CBG efficacy claim in the registry, and it did not find an effect — an absence of benefit that was measured, not an absence of research.
This was studied in people, and the results do not support it. A null result is a finding in its own right, often the most useful one we can report. The trial behind it is still in intake review and has no graded registry entry yet, so we describe it without a PMID link.